MXPA01010395A - Conjugados de cobalamina que son utiles como agentes antitumor. - Google Patents

Conjugados de cobalamina que son utiles como agentes antitumor.

Info

Publication number
MXPA01010395A
MXPA01010395A MXPA01010395A MXPA01010395A MXPA01010395A MX PA01010395 A MXPA01010395 A MX PA01010395A MX PA01010395 A MXPA01010395 A MX PA01010395A MX PA01010395 A MXPA01010395 A MX PA01010395A MX PA01010395 A MXPA01010395 A MX PA01010395A
Authority
MX
Mexico
Prior art keywords
antitumor agents
conjugates useful
compounds
cobalamin conjugates
cobalamin
Prior art date
Application number
MXPA01010395A
Other languages
English (en)
Inventor
Henricus P C Hogenkamp
Original Assignee
Mayo Of Foundation For Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Of Foundation For Medical filed Critical Mayo Of Foundation For Medical
Publication of MXPA01010395A publication Critical patent/MXPA01010395A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/06—Cobalt compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion provee compuestos de cobalamina ligados a un blanco para terapia de captura de neutrones (por ejemplo Boro-10 o Gadolinio-157), y ligados opcionalmente a una porcion que pueda ser detectada, asi como composiciones farmaceuticas que comprenden a los compuestos, y metodos para utilizar los compuestos en diagnosis y terapia medica.
MXPA01010395A 1999-04-16 2000-04-15 Conjugados de cobalamina que son utiles como agentes antitumor. MXPA01010395A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12973399P 1999-04-16 1999-04-16
US15987399P 1999-10-15 1999-10-15
PCT/US2000/010100 WO2000062808A2 (en) 1999-04-16 2000-04-15 Cobalamin conjugates useful as antitumor agents

Publications (1)

Publication Number Publication Date
MXPA01010395A true MXPA01010395A (es) 2004-08-12

Family

ID=26827868

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01010395A MXPA01010395A (es) 1999-04-16 2000-04-15 Conjugados de cobalamina que son utiles como agentes antitumor.

Country Status (7)

Country Link
EP (1) EP1171162A2 (es)
JP (1) JP2002542207A (es)
KR (1) KR20020032421A (es)
AU (1) AU4243700A (es)
CA (1) CA2370419A1 (es)
MX (1) MXPA01010395A (es)
WO (1) WO2000062808A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
AU785505B2 (en) * 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
EP1231942A1 (en) * 1999-10-15 2002-08-21 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
AU2002239719A1 (en) * 2000-10-25 2002-06-03 Mayo Foundation For Medical Education And Research Transcobalamin receptor binding conjugates for neutron capture therapy
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
SE0203823D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel Compounds
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
CA2550657A1 (en) * 2003-12-22 2005-07-07 Solidago Ag Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation
CN112442095B (zh) * 2020-12-01 2022-07-22 上海科黛生物科技有限公司 一种维生素b12的精制方法及所得产品的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5222134A (en) * 1990-11-07 1993-06-22 Tau Systems Corporation Secure system for activating personal computer software at remote locations
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
AU738431B2 (en) * 1996-08-27 2001-09-20 University Of Utah Research Foundation Bioconjugates and delivery of bioactive agents
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel

Also Published As

Publication number Publication date
KR20020032421A (ko) 2002-05-03
CA2370419A1 (en) 2000-10-26
WO2000062808A3 (en) 2001-02-22
AU4243700A (en) 2000-11-02
WO2000062808A8 (en) 2001-12-06
JP2002542207A (ja) 2002-12-10
WO2000062808A2 (en) 2000-10-26
EP1171162A2 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
EP1033981A4 (en) FORMULATIONS AND METHODS FOR REDUCING THE TOXICITY OF ANTINEOPLASTIC AGENTS
EP2353611A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
TR200002541T2 (tr) Topiramatın farmasötik bilişimi
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
SE9704545D0 (sv) Novel compounds
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
PL340906A1 (en) Adamantane derivatives
SE9904505D0 (sv) Novel compounds
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
MXPA01010395A (es) Conjugados de cobalamina que son utiles como agentes antitumor.
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
MY134880A (en) Thiazolyl amide derivatives
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
AU7374194A (en) Polyamino paramagnetic chelates which contain both phosphonate and non-phosphonate moieties for mri
AU2002215904A1 (en) Compounds with a branched linker
ES2144054T3 (es) Complejos de tri(platino).
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
DE60029084D1 (de) Neue depsipeptid-verbindung
ATE338567T1 (de) Pharmazeutische zubereitungen, wirkstoffe enthaltend, die sich für unerlaubte verabreichung anbieten
AP2001002369A0 (en) Pharmaceutical complex.
EP1594513A4 (en) CARBOHYDRATE CONJUGATES FOR PREVENTING THE ABUSE OF CONTROLLED SUBSTANCES

Legal Events

Date Code Title Description
FG Grant or registration